Brokerages expect that Davita Inc (NYSE:DVA) will report sales of $2.85 billion for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Davita’s earnings, with the lowest sales estimate coming in at $2.81 billion and the highest estimate coming in at $2.90 billion. Davita reported sales of $2.89 billion during the same quarter last year, which indicates a negative year-over-year growth rate of 1.4%. The company is expected to report its next quarterly earnings results on Wednesday, August 7th.

On average, analysts expect that Davita will report full-year sales of $11.38 billion for the current fiscal year, with estimates ranging from $11.15 billion to $11.53 billion. For the next year, analysts anticipate that the company will post sales of $11.88 billion, with estimates ranging from $11.62 billion to $12.10 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Davita.

Davita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.91 EPS for the quarter, missing the Zacks’ consensus estimate of $0.95 by ($0.04). The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.82 billion. Davita had a net margin of 1.15% and a return on equity of 13.96%. The company’s revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.05 earnings per share.

Several brokerages recently weighed in on DVA. William Blair reaffirmed a “buy” rating on shares of Davita in a research report on Thursday, June 20th. Zacks Investment Research upgraded shares of Davita from a “sell” rating to a “hold” rating in a research note on Friday, May 10th. Finally, Deutsche Bank reduced their price target on shares of Davita from $68.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $67.78.

Large investors have recently made changes to their positions in the business. Rehmann Capital Advisory Group boosted its position in Davita by 467.3% in the 1st quarter. Rehmann Capital Advisory Group now owns 556 shares of the company’s stock valued at $30,000 after buying an additional 458 shares during the period. CSat Investment Advisory L.P. increased its stake in shares of Davita by 61.8% during the fourth quarter. CSat Investment Advisory L.P. now owns 581 shares of the company’s stock worth $30,000 after acquiring an additional 222 shares during the period. Clearbridge Investments LLC grew its position in Davita by 63.5% during the first quarter. Clearbridge Investments LLC now owns 798 shares of the company’s stock worth $43,000 after buying an additional 310 shares during the period. Quadrant Capital Group LLC lifted its holdings in shares of Davita by 2,481.1% in the first quarter. Quadrant Capital Group LLC now owns 955 shares of the company’s stock valued at $50,000 after purchasing an additional 918 shares in the last quarter. Finally, First Interstate Bank purchased a new stake in shares of Davita in the first quarter valued at about $65,000. 87.65% of the stock is owned by hedge funds and other institutional investors.

Shares of DVA traded up $2.10 during mid-day trading on Wednesday, hitting $54.65. The company’s stock had a trading volume of 3,383,601 shares, compared to its average volume of 1,746,595. Davita has a fifty-two week low of $43.40 and a fifty-two week high of $79.11. The company has a 50-day moving average of $50.62. The company has a market cap of $8.96 billion, a PE ratio of 15.31, a price-to-earnings-growth ratio of 0.63 and a beta of 1.58. The company has a debt-to-equity ratio of 2.06, a current ratio of 1.12 and a quick ratio of 1.11.

About Davita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Further Reading: What can cause a stock to outperform?

Get a free copy of the Zacks research report on Davita (DVA)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with's FREE daily email newsletter.